Bringing the fundamentals into focus…
Back to Veradermics, Incorporated
How Veradermics, Incorporated stacks up
MANE · against 223 other Healthcare companies of similar size
Valuation
33/ 100
Below the middle of the pack.
Ranked #163 of 224 · scores higher than 26% of peers
Bars: peers in each 10-point band of the valuation score18 peers with a valuation score of 30–39, including MANE · Click a bar to see the companies
Why valuation scores 33?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield, which is weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -1.7% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -1.4% vs peer median 0.0%
- EBITDA yield is not reported, so it is left out of the score.
Metric by metric
Position: dot = MANE, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | MANE | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 221 reported | -1.9% | 2.5% | 23% | 30% | |
| EBITDA yieldHigher is better · 222 reported | Not reported | 4.5% | — | — | 50% |
| Free cash flow yieldHigher is better · 125 reported | -1.4% | 1.0% | 36% | 20% | |
| Book yieldHigher is better · 222 reported | 14.6% | 24.4% | 31% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around MANE| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 3 | 428.3B JPY (≈$2.9B) | 98 | 59 | |
| 4 | 22.0B CNY (≈$3.1B) | 96 | 67 | |
| 4 | 10.4B USD | 96 | 64 | |
| 158 | 10.1B USD | 37 | 61 | |
| 162 | 3.1B USD | 36 | 53 | |
| 163 | 6.1B USD | 33 | ||
| 163 | 4.5B USD | 33 | 33 | |
| 163 | 5.6B USD | 33 | 53 | |
| 163 | 8.8B USD | 33 | 50 | |
| 163 | 3.3B USD | 33 | 39 | |
| 168 | 8.9B USD | 32 | 51 | |
| 168 | 3.0B CHF (≈$3.5B) | 32 | 33 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score